Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function

Angiology

Volumn 56, Issue 4, 2005, Pages 439-449

  Zakynthinos, E ^a,b,c   Pierrutsakos, Ch ^a,b   Daniil, Z ^a,b   Papadogiannis, D ^a,c  

^a University of Athens Medical School ^*

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN;

ADULT; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHLETE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE MASS INDEX; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART SYSTOLIC FUNCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE SEPTUM; HOLTER MONITORING; HUMAN; HYPERTENSION; MALE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ARRHYTHMIA; BLOOD PRESSURE; COMORBIDITY; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; TREATMENT FAILURE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 22844436125     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600412     Document Type: Article

References (40)

1. Messerli FH, Ventura HO, Elizardi DJ, et al: Hypertension and sudden death: Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 77:18-22, 1984.
2. Levy D, Anderson KM, Savage DD, et al: Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108:7-13, 1988.
3. Levy D, Garrison RJ, Savage DD, et al: Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990.
4. McLenachan JM, Henderson E, Morris KI, et al: Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 317:787-792, 1987.
5. Nunez BD, Lavie CJ, Messerli FH, et al: Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol 74:585-589, 1994.
6. Melina D, Colivicchi F, Guerrera G, et al: Prevalence of left ventricular hypertrophy and cardiac arrhythmias in borderline hypertension. Am J Hypertens 5:570-573, 1992.
7. Pringle SD, Dunn FG, Macfarlane PW, et al: Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 69:913-917, 1992.
8. Palatini P, Maraglino G, Accurso V, et al: Impaired left ventricular filling in hypertensive left ventricular hypertrophy as a marker of the presence of an arrhythmogenic substrate. Br Heart J 73:258-262, 1995.
9. Ghali JK, Kadakia S, Cooper RS, et al: Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 17:1277-1282, 1991.
10. Dahlöf B: Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press 52:35-40, 1994.
11. Tedesco MA, Ratti G, Aquino D, et al: Effects of losartan on hypertension and left ventricular mass: A long-term study. J Hum Hypertens 12:505-510, 1998.
12. Klingbeil AU, Muller HJ, Delles C, et al: Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am J Hypertens 13:1295-1300, 2000.
13. Omvik P, Gerdts E, Myking OL, et al: Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension. Am Heart J 140:624-630, 2000.
14. Shibasaki Y, Masaki H, Nishiue T, et al: Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 90:256-261, 2002.
15. Dahlöf B: Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 14:174-182, 2001.
16. Hernandez-Hernandez R, Sosa-Canache B, Velasco M, et al: Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 16S:S93-S99, 2002.
17. Lee YM, Peng YY, Ding YA, et al: Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats. Am J Hypertens 10:852-858, 1997.
18. Thomas GP, Ferrier GR, Howlett SE: Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharmacol Exp Ther 278:1090-1097, 1996.
19. Pitt B, Segal R, Martinez FA, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752, 1997.
20. Kaplan NM: Systemic hypertension: Mechanisms and diagnosis. In: Heart Disease, ed. 5, ed. by Braunwald E. Philadelphia: WB Saunders, 1997, pp 807-839.
21. Sahn DJ, De Maria A, Kisslo J, et al: Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58:1072-1083, 1978.
22. Reichek N, Devereux RB: Left ventricular hypertrophy: Relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 63: 1391-1398, 1981.
23. Otto CM, Pearlman AS: Textbook of Clinical Echocardiography. Philadelphia: WB Saunders, 1995, pp 35-63.
24. Lown B, Wolf M: Approaches to sudden death from coronary heart disease. Circulation 46:130-139, 1971.
25. Vardas PE, Simandirakis EN, Parthenakis FI, et al: Study of late potentials and ventricular arrhythmias in hypertensive patients with normal electrocardiograms. Pace 17:576-584, 1994.
26. Lavie CJ, Nunez BD, Garavaglia GE, et al: Hypertensive concentric left ventricular hypertrophy: When is ventricular ectopic activity increased? South Med J 81:696-700, 1988.
27. Zakynthinos E, Vassilakopoulos T, Mavrommati I, et al: Echocardiographic and ambulatory electrocardiographic findings in elite water-polo athletes. Scand J Med Sci Sports 11:149-155, 2001.
28. Israili ZH: Clinical pharmacokinetics of angiotensin II (ATI) receptor blockers in hypertension. J Hum Hypertens 14S;S73-S86, 2002.
29. Papademetriou V, Narayan P, Kokkinos P: Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes. Am J Cardiol 73:242-246, 1994.
30. Messerli FH, Nunez BD, Nunez MM, et al: Hypertension and sudden death. Disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 149:1263-1267, 1989.
31. Kocemba J, Kawecka-Jaszcz K, Grodzicki T, et al: Influence of long-term treatment with nifedipine on blood pressure, left ventricular mass and cardiac arrhythmias in elderly hypertensive patients. J Hum Hypertens 8:279-282, 1994.
32. Mayet J, Chapman N, Shahi M, et al: The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. Am J Hypertens 10:611-618, 1997.
33. Gavras I, Gavras H: The antiarrhythmic potential of angiotensin II antagonism; Experience with losartan. Am J Hypertens 13:512-517, 2000.
34. Zhu B, Sun Y, Sievers RE, et al: Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 35:787-795, 2000.
35. Pitt B, Poole-Wilson PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587, 2000.
36. Diez J, Laviades C, Mayor G, et al: Increased serum concentration of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 91:1450-1456, 1995.
37. Gottdiener JS: Left ventricular mass, diastolic dysfunction, and hypertension. Adv Intern Med 38:31-56, 1993.
38. Cameron JS, Myerburg RJ, Wong SS, et al: Electrophysiologic consequences of chronic experimentally induced left ventricular pressure overload. J Am Coll Cardiol 2:481-487, 1983.
39. Dussaillant GR, Gonzalez H, Cespedes C, et al: Regression of left ventricular hypertrophy in experimental renovascular hypertension: Diastolic dysfunction depends more on myocardial collagen than it does on myocardial mass. J Hypertens 14:1117-1123, 1996.
40. Madrid AH, Bueno MG, Rebollo JMG, et al: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 106:331-336, 2002.